Roles of metabolic tumor volume and total lesion glycolysis on 18F-FDG PET/CT, CA19-9 levels, and complete blood parameters in predicting survival in patients with unresectable or metastatic pancreatic cancer

Basit Öğe Kaydı
dc.contributor.authorErdur, Erkan
dc.contributor.authorGuzel, Yunus
dc.contributor.authorYildirim, Ozgen Ahmet
dc.contributor.authorPoyraz, Kerem
dc.contributor.authorYildirim, Mehmet Serdar
dc.contributor.authorKaplan, Ilsan
dc.date.accessioned2024-04-24T17:44:46Z
dc.date.available2024-04-24T17:44:46Z
dc.date.issued2022
dc.departmentDicle Üniversitesien_US
dc.description.abstractAIM: In this study, we aimed to investigate the roles of volume based F-18-FDG PET/CT parameters, CA19-9 levels, and complete blood count parameters in predicting survival in patients with unresectable and/or metastatic pancreatic ductal adenocarcinoma. MATERIALS AND METHOD: Fifty-seven pancreatic cancer patients who were followed in University of Health Sciences Gazi Yasargil Training and Research Hospital between January 2017 and June 2020, declined surgical treatment and/or radiation therapy or had medically inoperable, unresectable, or metastatic disease, and received chemotherapy were included in the study. F-18-FDG PET/CT images of patients were evaluated and calculated metabolic tumor volume (MTV) and total lesion glycolysis (TLG) parameters were compared with CA19-9 levels and complete blood count parameters. Patients were assessed in two groups as survivors and non-survivors. RESULTS: Total MTV and total TLG on F-18-FDG PET/CT were significantly higher among non-survivors than survivors (p: 0.023 and 0.034, respectively). Multivariate Cox regression analysis revealed that TLG higher than 46 g/ml.cm(3), MTV higher than 11.02 cm(3) (OR 0.987, 95%CI 0.976-0.999, p:0.029 and OR 0.246, 95%CI 0.089-0.685, p: 0.007, respectively) and elevated MPV (OR:0.785, 95% CI 0,574-0.976, p:0.042) were independent prognostic factors for predicting mortality. CONCLUSION: TLG >46 g/ml.cm(3) and MTV >11.02 cm(3) in F-18-FDG PET/CT and elevated MPV in complete blood count are independent prognostic factors for predicting mortality in patients with unresectable or metastatic pancreatic cancer who are treated with chemotherapy.en_US
dc.identifier.endpage58en_US
dc.identifier.issn0003-469X
dc.identifier.issn2239-253X
dc.identifier.issue1en_US
dc.identifier.startpage48en_US
dc.identifier.urihttps://hdl.handle.net/11468/22278
dc.identifier.volume93en_US
dc.identifier.wosWOS:000886951900008
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.language.isoenen_US
dc.publisherEdizioni Luigi Pozzien_US
dc.relation.ispartofAnnali Italiani Di Chirurgia
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectPancreatic Canceren_US
dc.subjectMetabolic Tumor Volumeen_US
dc.subjectTotal Lesion Glycolysisen_US
dc.subjectMean Platelet Volumeen_US
dc.titleRoles of metabolic tumor volume and total lesion glycolysis on 18F-FDG PET/CT, CA19-9 levels, and complete blood parameters in predicting survival in patients with unresectable or metastatic pancreatic canceren_US
dc.titleRoles of metabolic tumor volume and total lesion glycolysis on 18F-FDG PET/CT, CA19-9 levels, and complete blood parameters in predicting survival in patients with unresectable or metastatic pancreatic cancer
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu